We are witnessing a long-awaited transformation in depression care. After decades of incremental change, new therapeutic ...
Recordati has received an unsolicited takeover offer from private equity group CVC Capital Partners that, if completed, would ...
AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease ...
At its second attempt, Rocket Pharma has won FDA approval for its gene therapy for severe leukocyte adhesion deficiency type ...
With the ink barely dry on one takeover agreement, Novartis has signed another, promising to pay up to $2 billion to acquire ...
"Screening is typically recommended for patients with confirmed liver cirrhosis or severe liver disease, since many cases of ...
Almost four months ahead of schedule, Corcept Therapeutics' selective glucocorticoid receptor antagonist (SGRA) relacorilant ...
Every clinical trial is built on the promise that the risk is justified by the strength of the evidence supporting it.
The data reveal from the phase 1 INLIGHT study of WVE-007 – an oligonucleotide-based gene-silencing drug designed to switch ...
The GLP-1 market is huge and growing, and depending on how patients acquire and pay for their therapies, traditional data ...
Denali Therapeutics' Avlayah is the first drug for neurological complications associated with the rare lysosomal storage ...
What is less often examined is how healthcare professionals actually experience survey design, and where common research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results